Mahboobeh Sadat Hosseini

Mahboobeh Sadat Hosseini

Auto-generated profile, based on publicly available information

Mahboobeh Sadat Hosseini

Health Research Center, Lifestyle institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Clinical Nutrition
Verified
Journal Article
Closed access
YPYunes Panahi
Yunes Panahi
MHMahboobeh Sadat Hosseini
Mahboobeh Sadat Hosseini
NKNahid Khalili
Nahid Khalili
ENEffat Naimi
Effat Naimi
MMMuhammed Majeed
Muhammed Majeed
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

1 August 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
YPYunes Panahi
Yunes Panahi
MHMahboobeh Sadat Hosseini
Mahboobeh Sadat Hosseini
NKNahid Khalili
Nahid Khalili
ENEffat Naimi
Effat Naimi
LSLuis E. Simental-Mendía
Luis E. Simental-Mendía
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

1 October 2014 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
YPYunes Panahi
Yunes Panahi
NKNahid Khalili
Nahid Khalili
MHMahboobeh Sadat Hosseini
Mahboobeh Sadat Hosseini
MAMohammad Abbasinazari
Mohammad Abbasinazari
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

1 October 2016 in Nutrition
Verified
Journal Article
Closed access
YPYunes Panahi
Yunes Panahi
MHMahboobeh Sadat Hosseini
Mahboobeh Sadat Hosseini
NKNahid Khalili
Nahid Khalili
ENEffat Naimi
Effat Naimi
SSSara Saffar Soflaei
Sara Saffar Soflaei
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

5 July 2014 in Nephro-Urology Monthly
Verified
Journal Article
Open access
PDF file
MHMahboobeh Sadat Hosseini
Mahboobeh Sadat Hosseini
ZRZohreh Rostami
Zohreh Rostami
ASAlireza Saadat
Alireza Saadat
SSSayyed Mehdi Saadatmand
Sayyed Mehdi Saadatmand
ENEffat Naeimi
Effat Naeimi
Background: Although chronic kidney disease-induced anemia is more prevalent in patients with diabetes mellitus (DM), anemia is a common finding prior to manifestation of kidney disease. In presence of some risk factors at the time of diagnosing DM, microvascular complications must be considered. The effect of anemia as a risk factor on progression of DM complications is still unclear. Objectives: The aim of the study was to determine the prevalence of anemia and its association with microvascular complications in patients with type 2 DM. Patients and Methods: This cross-sectional study was performed in the outpatient endocrinology clinic at Baqiyatallah University of Medical Sciences Hospital, Tehran, Iran. Study was done from February 2011 to February 2012. Patients with type 2 DM without any obvious symptom or sign of anemia were included in study. Results: A total of 93 patients (30.4%) had anemia including 46 (15.1%) with normochromic normocytic, 44 (14.4%) with hyperchromic microcytic, and 3 (1%) with hyperchromic macrocytic anemias. There was a positive correlation between duration of DM and anemia. Microvascular complications were more frequent with normocytic or microcytic anemias. Glomerular filtration rate (GFR) was higher in patients without anemia; moreover, nephropathy was less frequent among them. Among patients with anemia, 43% had GFR of more than 90 mL/min and 19.4% had normoalbuminuria. Neuropathy, nephropathy, and retinopathy had strong association with anemia (odds ratio of 1.99, 1.7, and 1.5, respectively). Conclusions: Anemia is a common complication of DM and is associated with duration of disease and microvascular complications. Keywords: Anemia; Diabetes Mellitus; Microvascular Complications

1 January 2010 in Indian Journal of Dermatology
Verified
Journal Article
Open access
PDF file
PNPedram Noormohammadpour
Pedram Noormohammadpour
AEAmirhooshang Ehsani
Amirhooshang Ehsani
NENafiseh Esmaily
Nafiseh Esmaily
STSiavash Toosi
Siavash Toosi
AHAlireza Hosseinpour
Alireza Hosseinpour
SSShima Sayanjali
Shima Sayanjali
Background: Pityriasis Rosea (PR) is an acute inflammatory and self-limiting skin disorder, sometimes with troublesome symptoms. To date, there are few treatments available for this disorder. Aim: Compare the traditional treatment with erythromycin to a newly introduced antiviral treatment acyclovir for PR. Materials and Methods: Patients with clinically confirmed diagnosis of PR, matching our exclusion criteria, were enrolled. They were randomized in two groups that received high-dose oral acyclovir or erythromycin. The participants were evaluated two, four, and eight weeks after commencement of the study and followed for one year. Results: A total of 30 patients including 15 males and 15 females completed the study. After eight weeks, 13 patients in the acyclovir group experienced complete response, while in the erythromycin group only six patients had complete response (P < 0.05). Also, patients in the acyclovir group experienced faster resolution of pruritus in comparison with the erythromycin group (not significant). No adverse drug reaction was detected in both groups. Conclusion: It seemed that a high-dose of oral acyclovir was a safe and effective therapy for PR, although this remained to be confirmed in larger studies.